Published in Stem Cell Res on October 08, 2011
Extensive genetic variation in somatic human tissues. Proc Natl Acad Sci U S A (2012) 1.56
Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet (2012) 1.38
Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat Commun (2014) 1.15
A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets. Stem Cell Reports (2014) 0.96
Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines from a single donor. Stem Cells Transl Med (2014) 0.93
Defining cell-matrix combination products in the era of pluripotency. Biomatter (2013) 0.78
Nucleosome positioning changes during human embryonic stem cell differentiation. Epigenetics (2016) 0.76
A novel lineage restricted, pericyte-like cell line isolated from human embryonic stem cells. Sci Rep (2016) 0.75
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Methods for high-density admixture mapping of disease genes. Am J Hum Genet (2004) 12.02
Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol (2003) 9.15
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med (2002) 8.33
Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature (2009) 8.12
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A (2009) 5.39
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet (2007) 5.09
A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet (2005) 5.02
The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet (2008) 4.79
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 3.90
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 3.55
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol (2005) 3.03
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol (2006) 2.77
Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet (2010) 2.64
Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol (2005) 2.60
Parthenogenetic stem cells in nonhuman primates. Science (2002) 2.54
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A (2009) 2.31
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet (2009) 2.30
Human embryonic stem cells derived without feeder cells. Lancet (2005) 2.24
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 2.20
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium. Stem Cells (2005) 2.09
Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med (2010) 2.09
A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol (2007) 1.99
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
Generation of histocompatible tissues using nuclear transplantation. Nat Biotechnol (2002) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum (2009) 1.87
Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol (2011) 1.86
Embryonic and extraembryonic stem cell lines derived from single mouse blastomeres. Nature (2005) 1.86
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci U S A (2011) 1.74
Multiple sclerosis: Prospects and promise. Ann Neurol (2013) 1.73
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet (2011) 1.69
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol (2008) 1.59
Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol (2004) 1.59
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet (2013) 1.55
Toward male individualization with rapidly mutating y-chromosomal short tandem repeats. Hum Mutat (2014) 1.53
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension (2013) 1.52
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 1.47
Is there an antiaging medicine? J Gerontol A Biol Sci Med Sci (2002) 1.46
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Isolation and characterization of novel rhesus monkey embryonic stem cell lines. Stem Cells (2006) 1.41
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail (2006) 1.41
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens (2009) 1.40
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine (2010) 1.37
B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest (2012) 1.35
A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis. Genetics (2003) 1.31
Protocols for cytogenetic studies of human embryonic stem cells. Methods (2008) 1.30
Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. Hum Mol Genet (2004) 1.29
Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy (2002) 1.28
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics (2006) 1.27
Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A (2008) 1.27
The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am J Hum Genet (2005) 1.26
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation (2012) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Early editorial manuscript screening versus obligate peer review: a randomized trial. Ann Neurol (2007) 1.23
Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog (2007) 1.22
Sequencing complex diseases With HapMap. Genetics (2004) 1.22
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics (2011) 1.20
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Nonhuman primate parthenogenetic stem cells. Proc Natl Acad Sci U S A (2003) 1.19
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
Copy number variation in African Americans. BMC Genet (2009) 1.18